Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News 4D Molecular Therapeutics Inc FDMT

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti... see more

Current News (NDAQ:FDMT)

4DMT Announces New Employment Inducement Grants

GlobeNewswire 4 days ago

4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire 8 days ago

NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

GlobeNewswire November 20, 2025

4DMT to Participate in 8th Annual Evercore Healthcare Conference

GlobeNewswire November 20, 2025

4DMT Appoints Kristian Humer as Chief Financial Officer

GlobeNewswire November 17, 2025

4DMT Announces New Employment Inducement Grants

GlobeNewswire November 14, 2025

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

GlobeNewswire November 10, 2025

4DMT to Participate in Jefferies 2025 London Healthcare Conference

GlobeNewswire November 6, 2025

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire November 6, 2025
View More News ››

Opinion & Analysis (NDAQ:FDMT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:FDMT)

Using technical analysis for this stock.

It is showing a steady uptrend for shareholders of this one today and tomorrow
coolfooldumbguy - August 1, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT): A Promising B

http://beyondspx.com/2024/07/31/4d-molecular-therapeutics-inc-nasdaqfdmt-a-promising-biotech-poised-for-growth/
MikeTester - August 2, 2024
View more Bullboard ››

Birchtech Corp.

Birchtech Corp.

Birchtech Corp., an environmental services and technology company, engages in developing and delivering solutions to the ...
View More »